NEW YORK, NY / April 06, 2021 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.
A digital presentation named “First-in-Class Anticancer AAV-Based Gene
Therapy Based on the Destruction of NETs with Transgene Expression of DNase I in Liver” will showcase CLS’ data for the use of CLS-014 drug candidate for colorectl cancer. CLS has identified a new therapeutic target for the successful anticancer therapy for multiple cancers: tumor- and neutrophils- derived cell-free DNA. This cell-free DNA circulates freely in the bloodstream and is also present extracellularly in tumors and metastasis, which was shown to be a critical component of the tumor microenvironment . Thus, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies (and has been independently confirmed by leading universities and research groups). The Company uses smart AAV technology for the delivery of the DNase I gene to the liver, after which, hepatocytes start to produce recombinant human enzyme that destroys this cell-free DNA.
The data that will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics, and exemplifies how CLS’ cutting-edge gene therapy capabilities can be leveraged to potentiate first-line chemotherapy, decrease primary tumor growth and prevent metastases formation in colorectal cancer.
Poster presentation details:
First-in-Class Anticancer AAV-Based Gene Therapy Based on the Destruction of NETs with Transgene Expression of DNase I in Liver
1CLS Therapeutics Institute, New York, NY, 10013 USA
2Human Microbiological Institute, New York, NY, 10013 USA
3Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical
5 M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia.
Tuesday May 11, 2021 8:00 PM – 10:00 PM
Session Title: Cancer – Immunotherapy, Cancer Vaccines
Room: Digital Gallery
Final abstract number: 629
Abstracts will be also available on the ASGCT website. The poster presentations to be presented at the 2021 ASGCT Annual Meeting will be available on the CLS Therapeutics website after May 11, 2021.
NEW YORK, March 29, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Cancer Metabolism and Signaling” being held on May 9, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.
NEW YORK, NY / July, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.